Polymorphisms of toll-like receptors and their pathways in viral hepatitis

Antiviral Therapy

Volumn 16, Issue 4, 2011, Pages 443-458

  Sawhney, Rohit ^a,b   Visvanathan, Kumar ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; LAMIVUDINE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2;

ADAPTIVE IMMUNITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; CAUCASIAN; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE SEVERITY; ENZYME ACTIVATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HEPATITIS B; HEPATITIS C; HOMOZYGOSITY; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; NATURAL KILLER T CELL; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS HEPATITIS; VIRUS LOAD; VIRUS REPLICATION;

ACUTE DISEASE; HEPATITIS B; HEPATITIS B, CHRONIC; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, INNATE; POLYMORPHISM, SINGLE NUCLEOTIDE; TOLL-LIKE RECEPTORS;

EID: 79959458019     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1820     Document Type: Review

References (162)

1. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5:975-979. (Pubitemid 41057713)
2. Hornef MW, Henriques-Normark B, Normark S. The function and biological role of Toll-like receptors in infectious diseases: an update. Curr Opin Infect Dis 2008; 21:304-312. (Pubitemid 351620386)
3. Tsujimoto H, Ono S, Efron PA, et al. Role of Toll-like receptors in the development of sepsis. Shock 2008; 29:315-321. (Pubitemid 351271701)
4. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009; 58:704-720.
5. Testro AG, Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol 2009; 24:943-954.
6. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-397.
7. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406:782-787.
8. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801. (Pubitemid 43261452)
9. Barton GM, Medzhitov R. Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol 2002; 14:380-383. (Pubitemid 34327982)
10. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-995. (Pubitemid 41057715)
11. Hopkins PA, Sriskandan S. Mammalian Toll-like receptors: to immunity and beyond. Clin Exp Immunol 2005; 140:395-407. (Pubitemid 40813950)
12. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25:187-191. (Pubitemid 30394990)
13. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000; 68:6398-6401.
14. Schröder NW, Diterich I, Zinke A, et al. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol 2005; 175:2534-2540. (Pubitemid 41113865)
15. Hawn TR, Misch EA, Dunstan SJ, et al. A common human TLR1 polymorphism regulates the innate immune response to lipopeptides. Eur J Immunol 2007; 37:2280-2289. (Pubitemid 47250219)
16. Hawn TR, Verbon A, Lettinga KD, et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med 2003; 198:1563-1572. (Pubitemid 37467170)
17. Oh DY, Baumann K, Hamouda O, et al. A frequent functional Toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS 2009; 23:297-307.
18. Wurfel MM, Gordon AC, Holden TD, et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 2008; 178:710-720.
19. Schwartz DA, Cook DN. Polymorphisms of the Toll-like receptors and human disease. Clin Infect Dis 2005; 41 Suppl 7:S403-S407. (Pubitemid 41598296)
20. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gramnegative septic shock. Arch Intern Med 2002; 162:1028-1032. (Pubitemid 34492532)
21. Agnese DM, Calvano JE, Hahm SJ, et al. Human Tolllike receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002; 186:1522-1525. (Pubitemid 35286126)
22. Schröder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005; 5:156-164. (Pubitemid 40568671)
23. Misch EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci (Lond) 2008; 114:347-360. (Pubitemid 351397384)
24. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359:1766-1777.
25. Pulido I, Leal M, Genebat M, et al. The TLR4 ASP299GLY polymorphism is a risk factor for active tuberculosis in Caucasian HIV-infected patients. Curr HIV Res 2010; 8:253-258.
26. Hawn TR, Dunstan SJ, Thwaites GE, et al. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis 2006; 194:1127-1134. (Pubitemid 44547653)
27. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39:523-528. (Pubitemid 46514767)
28. Teuffel O, Ethier MC, Beyene J, Sung L. Association between tumor necrosis factor-alpha promoter -308 A/G polymorphism and susceptibility to sepsis and sepsis mortality: a systematic review and meta-analysis. Crit Care Med 2010; 38:276-282.
29. Cooper A, Tal G, Lider O, Shaul Y. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol 2005; 175:3165-3176. (Pubitemid 41170538)
30. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79:7269-7272. (Pubitemid 40677357)
31. Thompson AJ, Colledge D, Rodgers S, et al. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther 2009; 14:797-808.
32. Wu J, Lu M, Meng Z, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007; 46:1769-1778.
33. Chen Z, Cheng Y, Xu Y, et al. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008; 128:400-408.
34. Riordan SM, Skinner N, Kurtovic J, Locarnini S, Visvanathan K. Reduced expression of Toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol 2006; 13:972-974. (Pubitemid 44409640)
35. Visvanathan K, Skinner NA, Thompson AJ, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007; 45:102-110. (Pubitemid 46150869)
36. Xu Y, Hu Y, Shi B, et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 2009; 46:2640-2646.
37. Li N, Li Q, Qian Z, et al. Impaired TLR3/IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. Biochem Biophys Res Commun 2009; 390:630-635.
38. Xie Q, Shen HC, Jia NN, et al. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect 2009; 11:515-523.
39. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005; 23:5263-5270. (Pubitemid 41443432)
40. Ma R, Du JL, Huang J, Wu CY. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem Biophys Res Commun 2007; 361:537-542. (Pubitemid 47187279)
41. Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J Clin Immunol 2004; 24:693-701. (Pubitemid 40933121)
42. Yan CG, Ren GY, Wang F, Zhu DF, Zhuang Y. CD14-159 and -260 gene polymorphisms are associated with HBVrelated cirrhotic injury in Chinese Han patients. Chin J Physiol 2008; 51:94-99.
43. Zhou L, Wei B, Xing C, et al. Polymorphism in 3′-untranslated region of Toll-like receptor 4 gene is associated with protection from hepatitis B virus recurrence after liver transplantation. Transpl Infect Dis 2011; 13:250-258.
44. Dunn C, Peppa D, Khanna P, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009; 137:1289-1300.
45. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004; 101:6669-6674. (Pubitemid 38586032)
46. Fisicaro P, Valdatta C, Boni C, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009; 58:974-982.
47. Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81:4215-4225. (Pubitemid 46586915)
48. Duramad O, Fearon KL, Chan JH, et al. IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood 2003; 102:4487-4492. (Pubitemid 37494114)
49. Tu Z, Bozorgzadeh A, Pierce RH, et al. TLR-dependent cross talk between human Kupffer cells and NK cells. J Exp Med 2008; 205:233-244. (Pubitemid 351185729)
50. Zhang H, Gong Q, Li JH, et al. CpG ODN pretreatment attenuates concanavalin A-induced hepatitis in mice. Int Immunopharmacol 2010; 10:79-85.
51. Xiao X, Zhao P, Rodriguez-Pinto D, et al. Inflammatory regulation by TLR3 in acute hepatitis. J Immunol 2009; 183:3712-3719.
52. + NKT cells. J Immunol 2009; 182:3768-3774.
53. Kitazawa T, Tsujimoto T, Kawaratani H, Fujimoto M, Fukui H. Expression of Toll-like receptor 4 in various organs in rats with D-galactosamine-induced acute hepatic failure. J Gastroenterol Hepatol 2008; 23:e494-e498.
54. Akashi-Takamura S, Furuta T, Takahashi K, et al. Agonistic antibody to TLR4/MD-2 protects mice from acute lethal hepatitis induced by TNF-alpha. J Immunol 2006; 176:4244-4251. (Pubitemid 44264403)
55. Chang WW, Su IJ, Lai MD, et al. Toll-like receptor 4 plays an anti-HBV role in a murine model of acute hepatitis B virus expression. World J Gastroenterol 2005; 11:6631-6637.
56. Zhang Z, Zou ZS, Fu JL, et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J Hepatol 2008; 49:396-406.
57. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7:353-364. (Pubitemid 46674493)
58. Guo H, Jiang D, Ma D, et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 2009; 83:847-858.
59. Kumpf O, Giamarellos-Bourboulis EJ, Koch A, et al. Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Crit Care 2010; 14:R103.
60. Nagpal K, Plantinga TS, Wong J, et al. A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of MyD88 binding and reduced TLR2/TLR4 signaling. J Biol Chem 2009; 284:25742-25748.
61. George J, Kubarenko AV, Rautanen A, et al. MyD88 adaptor-like D96N is a naturally occurring loss-of-function variant of TIRAP. J Immunol 2010; 184:3025-3032.
62. Ramasawmy R, Cunha-Neto E, Fae KC, et al. Heterozygosity for the S180L variant of MAL/TIRAP, a gene expressing an adaptor protein in the Toll-like receptor pathway, is associated with lower risk of developing chronic Chagas cardiomyopathy. J Infect Dis 2009; 199:1838-1845.
63. Redpath S, Ghazal P, Gascoigne NR. Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol 2001; 9:86-92. (Pubitemid 32155327)
64. Eskdale J, Keijsers V, Huizinga T, Gallagher G. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1999; 1:151-155. (Pubitemid 129627293)
65. Lu YL, Wu X, Huang HL, Dai LC. Allele polymorphisms of interleukin-10 and hepatitis B, C virus infection. Chin Med J (Engl) 2010; 123:1338-1344.
66. Cheong JY, Cho SW, Hwang IL, et al. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J Gastroenterol Hepatol 2006; 21:1163-1169.
67. Ben-Ari Z, Mor E, Papo O, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003; 98:144-150. (Pubitemid 36135183)
68. Miyazoe S, Hamasaki K, Nakata K, et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002; 97:2086-2092.
69. Yan Z, Tan W, Zhao W, et al. Regulatory polymorphisms in the IL-10 gene promoter and HBV-related acute liver failure in the Chinese population. J Viral Hepat 2009; 16:775-783.
70. Wu JF, Wu TC, Chen CH, et al. Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology 2010; 138:165-172.e3.
71. Gao QJ, Liu DW, Zhang SY, et al. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol 2009; 15:5610-5619.
72. Chan HL, Tse AM, Chim AM, et al. Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B. J Gastroenterol Hepatol 2008; 23:783-789. (Pubitemid 351519419)
73. Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000; 46:540-545. (Pubitemid 30305820)
74. Du T, Guo XH, Zhu XL, et al. Association of TNF-alpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population. J Viral Hepat 2006; 13:618-624. (Pubitemid 44232546)
75. Li HQ, Li Z, Liu Y, et al. Association of polymorphism of tumor necrosis factor-alpha gene promoter region with outcome of hepatitis B virus infection. World J Gastroenterol 2005; 11:5213-5217. (Pubitemid 41410342)
76. Lu LP, Li XW, Liu Y, et al. Association of -238G/A polymorphism of tumor necrosis factor-alpha gene promoter region with outcomes of hepatitis B virus infection in Chinese Han population. World J Gastroenterol 2004; 10:1810-1814. (Pubitemid 38931211)
77. Park YK, Lee JM, Kim DY, et al. Association between polymorphism of tumor necrosis factor-alpha promoter and response to lamivudine treatment in patients with chronic hepatitis B. Dig Dis Sci 2010; 55:2043-2048.
78. Niro GA, Fontana R, Gioffreda D, et al. Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int 2005; 25:1175-1181. (Pubitemid 41782562)
79. Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat 2007; 14:841-848. (Pubitemid 350211408)
80. Park BL, Lee HS, Kim YJ, et al. Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med 2003; 35:76-82. (Pubitemid 36626937)
81. Dolganiuc A, Oak S, Kodys K, et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127:1513-1524. (Pubitemid 39457776)
82. Wang N, Liang Y, Devaraj S, et al. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol 2009; 83:9824-9834.
83. Takahashi K, Asabe S, Wieland S, et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci U S A 2010; 107:7431-7436.
84. Riordan SM, Skinner NA, Kurtovic J, et al. Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury. Inflamm Res 2006; 55:279-285. (Pubitemid 44359131)
85. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102:2992-2997. (Pubitemid 40299904)
86. Otsuka M, Kato N, Moriyama M, et al. Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses. Hepatology 2005; 41:1004-1012. (Pubitemid 40593908)
87. Abe T, Kaname Y, Hamamoto I, et al. Hepatitis C virus nonstructural protein 5A modulates the Toll-like receptor- MyD88-dependent signaling pathway in macrophage cell lines. J Virol 2007; 81:8953-8966. (Pubitemid 47311439)
88. Miyazaki M, Kanto T, Inoue M, et al. Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Tolllike receptors and retinoic acid inducible gene-I. J Med Virol 2008; 80:980-988. (Pubitemid 351657008)
89. Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2008; 47:385-395. (Pubitemid 351280706)
90. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 2007; 82:479-487. (Pubitemid 47367138)
91. Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces Toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 2006; 80:866-874. (Pubitemid 43062898)
92. Dolganiuc A, Norkina O, Kodys K, et al. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 2007; 133:1627-1636. (Pubitemid 350029734)
93. Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005; 42:724-731. (Pubitemid 41233667)
94. Charlton M, Wiesner R. Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis 2004; 24 Suppl 2:79-88. (Pubitemid 39180710)
95. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 Suppl 2:S36-S44.
96. Eid AJ, Brown RA, Paya CV, Razonable RR. Association between Toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation 2007; 84:511-516. (Pubitemid 47312163)
97. Brown RA, Gralewski JH, Eid AJ, et al. R753Q singlenucleotide polymorphism impairs toll-like receptor 2 recognition of hepatitis C virus core and nonstructural 3 proteins. Transplantation 2010; 89:811-815.
98. Askar E, Bregadze R, Mertens J, et al. TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C. J Med Virol 2009; 81:1204-1211.
99. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13:1324-1332. (Pubitemid 350073596)
100. Guo J, Loke J, Zheng F, et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Tolllike receptor 4 to hepatic stellate cell responses. Hepatology 2009; 49:960-968.
101. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46:297-306. (Pubitemid 47344763)
102. Li Y, Chang M, Abar O, et al. Multiple variants in Tolllike receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol 2009; 51:750-757.
103. Dhillon N, Walsh L, Kruger B, et al. A single nucleotide polymorphism of Toll-like receptor 4 identifies the risk of developing graft failure after liver transplantation. J Hepatol 2010; 53:67-72.
104. Schott E, Witt H, Neumann K, et al. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol 2007; 47:203-211. (Pubitemid 47021254)
105. Schott E, Witt H, Neumann K, et al. Association of TLR7 single nucleotide polymorphisms with chronic HCVinfection and response to interferon-a-based therapy. J Viral Hepat 2008; 15:71-78. (Pubitemid 350243584)
106. Askar E, Ramadori G, Mihm S. Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection. J Med Virol 2010; 82:1859-1868.
107. Du X, Poltorak A, Wei Y, Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw 2000; 11:362-371. (Pubitemid 32268893)
108. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002; 99:15669-15674. (Pubitemid 35403989)
109. Major ME, Dahari H, Mihalik K, et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 2004; 39:1709-1720. (Pubitemid 38702673)
110. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:1395-1406. (Pubitemid 33081515)
111. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatmentinduced viral clearance. Gastroenterology 2003; 125:80-88. (Pubitemid 36799109)
112. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117:933-941. (Pubitemid 29468237)
113. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13:34-41.
114. Asselah T, Bieche I, Paradis V, et al. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007; 27:13-27.
115. Thomson M, Nascimbeni M, Havert MB, et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 2003; 77:862-870. (Pubitemid 36055508)
116. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305:872-874. (Pubitemid 39038423)
117. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996; 24:6-9. (Pubitemid 26249404)
118. Chen TY, Hsieh YS, Wu TT, et al. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl Res 2007; 150:116-121.
119. Chen Y, Pei J. An assessment of a TNF polymorphic marker for the risk of HCV infection: meta-analysis and a new clinical study design. Infect Genet Evol 2009; 9:1356-1363.
120. Dai CY, Chuang WL, Lee LP, et al. Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C. J Viral Hepat 2006; 13:770-774.
121. Kusumoto K, Uto H, Hayashi K, et al. Interleukin-10 or tumor necrosis factor-alpha polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine 2006; 34:24-31. (Pubitemid 43817549)
122. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000; 1:386-390.
123. Dai CY, Chuang WL, Chang WY, et al. Tumor necrosis factor-alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis 2006; 193:98-101.
124. Thio CL, Goedert JJ, Mosbruger T, et al. An analysis of tumor necrosis factor alpha gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection. Genes Immun 2004; 5:294-300. (Pubitemid 38961163)
125. Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factorbeta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 2003; 71:212-218. (Pubitemid 37048464)
126. Constantini PK, Wawrzynowicz-Syczewska M, Clare M, et al. Interleukin-1, interleukin-10 and tumour necrosis factoralpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002; 22:404-412. (Pubitemid 35331401)
127. Schiemann U, Glas J, Torok P, et al. Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism. Digestion 2003; 68:1-4. (Pubitemid 37256039)
128. Yu ML, Dai CY, Chiu CC, et al. Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. Antiviral Res 2003; 59:35-40.
129. Rosen HR, McHutchison JG, Conrad AJ, et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97:714-720. (Pubitemid 34245903)
130. Yee LJ, Tang J, Gibson AW, et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33:708-712. (Pubitemid 32185234)
131. Abbott WG, Rigopoulou E, Haigh P, et al. Single nucleotide polymorphisms in the interferon-gamma and interleukin-10 genes do not influence chronic hepatitis C severity or T-cell reactivity to hepatitis C virus. Liver Int 2004; 24:90-97. (Pubitemid 38584993)
132. Minton EJ, Smillie D, Smith P, et al. Clearance of hepatitis C virus is not associated with single nucleotide polymorphisms in the IL-1, -6, or -10 genes. Hum Immunol 2005; 66:127-132. (Pubitemid 40208199)
133. Chuang JY, Yang SS, Lu YT, et al. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis 2009; 41:424-430.
134. Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30:526-530. (Pubitemid 29357520)
135. Mangia A, Santoro R, Piattelli M, et al. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine 2004; 25:103-109. (Pubitemid 38096267)
136. Knapp S, Hennig BJ, Frodsham AJ, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003; 55:362-369. (Pubitemid 37255487)
137. Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002; 36:271-277. (Pubitemid 34146435)
138. Bouzgarrou N, Hassen E, Farhat K, et al. Combined analysis of interferon-gamma and interleukin-10 gene polymorphisms and chronic hepatitis C severity. Hum Immunol 2009; 70:230-236.
139. Paladino N, Fainboim H, Theiler G, et al. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol 2006; 80:9144-9150. (Pubitemid 44359986)
140. Falleti E, Fabris C, Toniutto P, et al. Genetic polymorphisms of inflammatory cytokines and liver fibrosis progression due to recurrent hepatitis C. J Interferon Cytokine Res 2007; 27:239-246. (Pubitemid 46435492)
141. Tambur AR, Ortegel JW, Ben-Ari Z, et al. Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients. Transplantation 2001; 71:1475-1480. (Pubitemid 32507124)
142. Morgan TR, Lambrecht RW, Bonkovsky HL, et al. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol 2008; 49:548-556.
143. Oleksyk TK, Thio CL, Truelove AL, et al. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 2005; 6:347-357. (Pubitemid 40903408)
144. Welzel TM, Morgan TR, Bonkovsky HL, et al. Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral longterm treatment against cirrhosis trial. Hepatology 2009; 49:1847-1858.
145. Nattermann J, Vogel M, Berg T, et al. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology 2007; 46:1016-1025.
146. Pereira FA, Pinheiro da Silva NN, Rodart IF, et al. Association of TGF-beta1 codon 25 (G915C) polymorphism with hepatitis C virus infection. J Med Virol 2008; 80:58-64. (Pubitemid 350220089)
147. Yee LJ, Im K, Borg B, Yang H, Liang TJ. Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection. Genes Immun 2009; 10:365-372.
148. Yin LM, Zhu WF, Wei L, et al. Association of interleukin-12 p40 gene 3′-untranslated region polymorphism and outcome of HCV infection. World J
149. Houldsworth A, Metzner M, Rossol S, et al. Polymorphisms in the IL-12B gene and outcome of HCV infection. J Interferon Cytokine Res 2005; 25:271-276. (Pubitemid 40664424)
150. Mueller T, Mas-Marques A, Sarrazin C, et al. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. J Hepatol 2004; 41:652-658. (Pubitemid 39297802)
151. Hegazy D, Thurairajah P, Metzner M, et al. Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection. Clin Exp Immunol 2008; 152:538-541. (Pubitemid 351661506)
152. Lio D, Caruso C, Di Stefano R, et al. IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol 2003; 64:674-680. (Pubitemid 36828498)
153. Fensterl V, Grotheer D, Berk I, et al. Hepatitis A virus suppresses RIG-I-mediated IRF-3 activation to block induction of beta interferon. J Virol 2005; 79:10968-10977. (Pubitemid 41170638)
154. Qu L, Lemon SM. Hepatitis a and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses. Semin Liver Dis 2010; 30:319-332.
155. Arora R, Saha A, Malhotra D, et al. Promoter and intron-1 region polymorphisms in the IFNG gene in patients with hepatitis E. Int J Immunogenet 2005; 32:207-212. (Pubitemid 40768939)
156. Gupta V, Arora R, Saha A, et al. Novel variations in the signal peptide region of transforming growth factor beta1 gene in patients with hepatitis: a brief report from India. Int J Immunogenet 2005; 32:79-82. (Pubitemid 40461168)
157. Ferwerda B, McCall MB, Alonso S, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A 2007; 104:16645-16650. (Pubitemid 350211070)
158. Ferwerda B, McCall MB, Verheijen K, et al. Functional consequences of Toll-like receptor 4 polymorphisms. Mol Med 2008; 14:346-352. (Pubitemid 351785708)
159. Hang J, Zhou W, Zhang H, et al. TLR4 Asp299Gly and Thr399Ile polymorphisms are very rare in the Chinese population. J Endotoxin Res 2004; 10:238-240. (Pubitemid 39481013)
160. Cheng PL, Eng HL, Chou MH, You HL, Lin TM. Genetic polymorphisms of viral infection-associated Toll-like receptors in Chinese population. Transl Res 2007; 150:311-318.
161. Ferwerda B, Alonso S, Banahan K, et al. Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci U S A 2009; 106:10272-10277.
162. Hamann L, Kumpf O, Schuring RP, et al. Low frequency of the TIRAP S180L polymorphism in Africa, and its potential role in malaria, sepsis, and leprosy. BMC Med Genet 2009; 10:65.